Metavalis develops RNA‑based therapeutics aimed at treating diseases that are difficult to address with traditional small‑molecule drugs or protein biologics. By leveraging advanced RNA design and delivery platforms, the company creates precision medicines that can modulate disease‑causing genes directly. Their pipeline includes candidates targeting rare genetic disorders and other high‑unmet‑need conditions, offering a novel approach to intervene at the molecular level.
Funding
Funding not disclosed
Founders
Product
Problem
Many diseases, especially rare and complex conditions, lack effective treatments because traditional small‑molecule drugs cannot selectively modulate the underlying genetic or protein targets. This leaves patients with limited therapeutic options and unmet medical needs.
Solution
Metavalis applies a proprietary RNA‑based platform to design and deliver therapeutic RNA molecules that can precisely regulate disease‑relevant genes. By using engineered RNA sequences, the company can up‑ or down‑regulate target proteins that are otherwise inaccessible to conventional drugs. The platform integrates optimized delivery vectors and chemical modifications to enhance stability, tissue targeting, and cellular uptake. This approach enables rapid development of candidates for indications where existing therapies are insufficient, aiming to provide a precision medicine solution for rare and complex disorders.
Target Audience
Primary customers are biopharmaceutical companies and research organizations seeking RNA‑based therapeutic candidates for rare, genetically driven, or otherwise hard‑to‑treat diseases.
Features
- Customizable RNA design pipeline that selects sequences to modulate specific disease genes
- Advanced delivery technology employing lipid‑nanoparticle and conjugate systems for targeted tissue distribution
- Chemical modification suite to improve RNA stability, reduce immunogenicity, and extend circulation time
- Integrated preclinical validation workflow combining in‑vitro assays and animal models to assess efficacy and safety
- Scalable manufacturing process for GMP‑grade RNA therapeutics